Cargando…

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation

Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unkno...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Kazuhiko, Ueda, Koki, Sano, Takahiro, Ogawa, Kazuei, Ikezoe, Takayuki, Hashimoto, Yuko, Morishita, Soji, Komatsu, Norio, Ohto, Hitoshi, Takeishi, Yasuchika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519475/
https://www.ncbi.nlm.nih.gov/pubmed/28674362
http://dx.doi.org/10.2169/internalmedicine.56.7871
_version_ 1783251622019727360
author Ikeda, Kazuhiko
Ueda, Koki
Sano, Takahiro
Ogawa, Kazuei
Ikezoe, Takayuki
Hashimoto, Yuko
Morishita, Soji
Komatsu, Norio
Ohto, Hitoshi
Takeishi, Yasuchika
author_facet Ikeda, Kazuhiko
Ueda, Koki
Sano, Takahiro
Ogawa, Kazuei
Ikezoe, Takayuki
Hashimoto, Yuko
Morishita, Soji
Komatsu, Norio
Ohto, Hitoshi
Takeishi, Yasuchika
author_sort Ikeda, Kazuhiko
collection PubMed
description Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unknown. We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L). This case suggests that ruxolitinib is a treatment option for post-PV MF in patients with thrombocytopenia or JAK2 exon 12 mutations.
format Online
Article
Text
id pubmed-5519475
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-55194752017-07-27 The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation Ikeda, Kazuhiko Ueda, Koki Sano, Takahiro Ogawa, Kazuei Ikezoe, Takayuki Hashimoto, Yuko Morishita, Soji Komatsu, Norio Ohto, Hitoshi Takeishi, Yasuchika Intern Med Case Report Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unknown. We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L). This case suggests that ruxolitinib is a treatment option for post-PV MF in patients with thrombocytopenia or JAK2 exon 12 mutations. The Japanese Society of Internal Medicine 2017-07-01 /pmc/articles/PMC5519475/ /pubmed/28674362 http://dx.doi.org/10.2169/internalmedicine.56.7871 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Ikeda, Kazuhiko
Ueda, Koki
Sano, Takahiro
Ogawa, Kazuei
Ikezoe, Takayuki
Hashimoto, Yuko
Morishita, Soji
Komatsu, Norio
Ohto, Hitoshi
Takeishi, Yasuchika
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
title The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
title_full The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
title_fullStr The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
title_full_unstemmed The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
title_short The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
title_sort amelioration of myelofibrosis with thrombocytopenia by a jak1/2 inhibitor, ruxolitinib, in a post-polycythemia vera myelofibrosis patient with a jak2 exon 12 mutation
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519475/
https://www.ncbi.nlm.nih.gov/pubmed/28674362
http://dx.doi.org/10.2169/internalmedicine.56.7871
work_keys_str_mv AT ikedakazuhiko theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT uedakoki theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT sanotakahiro theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT ogawakazuei theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT ikezoetakayuki theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT hashimotoyuko theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT morishitasoji theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT komatsunorio theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT ohtohitoshi theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT takeishiyasuchika theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT ikedakazuhiko ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT uedakoki ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT sanotakahiro ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT ogawakazuei ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT ikezoetakayuki ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT hashimotoyuko ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT morishitasoji ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT komatsunorio ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT ohtohitoshi ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation
AT takeishiyasuchika ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation